Regulatory T Cell Mediator Proteins and Uses Thereof

Patent metadata

Field	Value
Publication number	US-2016168248-A1
Application number	US-201514940940-A
Country	US
Kind code	A1
Filing date	Nov 13, 2015
Priority date	Apr 25, 2005
Publication date	Jun 16, 2016
Grant date	—

Abstract

The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T reg -sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.
In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed

First claim

1 - 22 . (canceled)

23 . A method of inhibiting cytokine expression by CD4 + and/or CD8 + T cells in a subject by comprising the administration of an effective amount of a PD-L3 fusion protein.

24 . The method of claim 23 , wherein the PD-L3 fusion protein is a PD-L3-Ig fusion protein.

25 . The method of claim 23 , wherein the PD-L3 fusion protein comprise a PD-L3 polypeptide at least 90% identical to SEQ ID NO:4.

26 . The method of claim 23 , wherein the cytokines include gamma interferon and IL-2.

27 . A method of promoting Treg activity in a subject by comprising the administration of an effective amount of a PD-L3 fusion protein.

28 . The method of claim 27 , wherein the PD-L3 fusion protein is a PD-L3-Ig fusion protein.

29 . The method of claim 27 , wherein the PD-L3 fusion protein comprise a PD-L3 polypeptide at least 90% identical to SEQ ID NO:4.

Assignees

• Dartmouth College

Inventors

• Noelle Randolph J
• Wang Li

Classifications

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K16/2827 Primary

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/70596

  Molecules with a "CD"-designation not provided for elsewhere · CPC title

• A61K2039/505

  comprising antibodies · CPC title